BioSpace News Archive

Biotech Bay

Inscopix Showcases New Brain Mapping Technology and Key Scientific Presentations at the 50th Annual Meeting of the Society for Neuroscience

Inscopix Showcases New Brain Mapping Technology and Key Scientific Presentations at the 50th Annual Meeting of the Society for Neuroscience

November 8, 2021
·
5 min read
Business

Gyroscope Therapeutics Announces Sanofi Investment of Up to $60 Million

Gyroscope Therapeutics Holdings plc today announced that Sanofi, a global biopharmaceutical company, has committed to invest up to USD $60.0 million (GBP £44.5 million) in equity in Gyroscope.

November 8, 2021
·
5 min read
BioForest

Alpine Immune Sciences to Present ALPN-303 Data at American College of Rheumatology Convergence 2021 Annual Meeting

Alpine Immune Sciences, Inc. today announced a presentation in a Plenary session of the American College of Rheumatology (ACR) Convergence 2021 Annual Meeting.

November 8, 2021
·
6 min read
Vasomune Announces Government Financial Support for the Development of COVID-19 Therapeutic

Vasomune Receives a US $6.4 Million PRMRP Grant from the US Department of Defense and up to $2.8 Million from NRC IRAP to Support the Development of AV-001 for the Treatment of Patients with Severe COVID-19 Disease and COVID-associated ARDS

November 8, 2021
·
5 min read
Biotech Bay

ReCode Therapeutics to Participate in Upcoming November Investor Conferences

ReCode Therapeutics today announced that Company leadership will participate in two upcoming virtual investor conferences in November: 2021 Stifel Healthcare Conference Format: Live Presentation Date: Monday, November 15, 2021 Time: 4:40 p.m.

November 8, 2021
·
1 min read
Business

Aytu BioPharma to Report First Quarter Fiscal 2022 Results and Provide Business Update on November 15, 2021

Aytu BioPharma, Inc. announced today that it will host a conference call and live webcast on November 15, 2021, at 4:30 p.m. ET.

November 8, 2021
·
2 min read
Drug Development

Pieris Pharmaceuticals and Servier Announce Dosing of First Patient in Phase 1/2 Trial of 4-1BB/PD-L1 Bispecific PRS-344/S095012

Pieris Pharmaceuticals, Inc. today announced that the first patient has been dosed in the phase 1/2 study of PRS-344/S095012, a next generation 4-1BB/PD-L1 Anticalin-based bispecific for the treatment of solid tumors, triggering an undisclosed milestone payment to Pieris.

November 8, 2021
·
6 min read
Business

Vaccinex Reports Third Quarter 2021 Financial Results and Provides Corporate Update

Vaccinex, Inc. today announced financial results for the third quarter ended September 30, 2021 and provided a corporate update.

November 8, 2021
·
9 min read
Business

Landos Biopharma Announces Leadership Transition

Landos Biopharma Inc. today announced that Josep Bassaganya-Riera, Ph.D., has stepped down as Chairman, President and Chief Executive Officer, effective immediately.

November 8, 2021
·
8 min read
Drug Development

Selecta Biosciences Announces Top Line Data from the Phase I SEL-399 AAV Empty Capsid Study, Highlighting Potential Benefits of ImmTOR™ in Gene Therapy

Selecta Biosciences, Inc. today announced top-line results from a joint Selecta and AskBio Phase I randomized, placebo controlled, double blind, dose-escalation study to evaluate the potential of its ImmTOR™ platform in mitigating the formation of neutralizing antibodies against an adeno-associated viral serotype 8 (AAV8) serotype capsid used in gene therapies.

November 8, 2021
·
10 min read